 SAN DIEGO, Aug. 12, 2021 GLOBE NEWSWIRE -- Cidara Therapeutics, Inc. NASDAQ: CDTX, a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the second quarter ended June 30, 2021 and provided an update on its corporate activities and product pipeline. 